Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia


Abstract

Background: Phenobarbital and midazolam are commonly used drugs in (near-)term neonates treated with therapeutic hypothermia for hypoxic-ischaemic encephalopathy, for sedation, and/or as anti-epileptic drug. Phenobarbital is an inducer of cytochrome P450 (CYP) 3A, while midazolam is a...
CYP3A substrate. Therefore, co-treatment with phenobarbital might impact midazolam clearance. **Objectives:** To assess pharmacokinetics and clinical anti-epileptic effectiveness of phenobarbital and midazolam in asphyxiated neonates and to develop dosing guidelines. **Methods:** Data were collected in the prospective multicentre PharmaCool study. In the present study, neonates treated with therapeutic hypothermia and receiving midazolam and/or phenobarbital were included. Plasma concentrations of phenobarbital and midazolam including its metabolites were determined in blood samples drawn on days 2–5 after birth. Pharmacokinetic analyses were performed using non-linear mixed effects modelling; clinical effectiveness was defined as no use of additional anti-epileptic drugs. **Results:** Data were available from 113 (phenobarbital) and 118 (midazolam) neonates; 68 were treated with both medications. Only clearance of 1-hydroxy midazolam was influenced by hypothermia. Phenobarbital co-administration increased midazolam clearance by a factor 2.3 (95% CI 1.9–2.9, p < 0.05). Anticonvulsant effectiveness was 65.5% for phenobarbital and 37.1% for add-on midazolam. **Conclusions:** Therapeutic hypothermia does not influence clearance of phenobarbital or midazolam in (near-)term neonates with hypoxic-ischaemic encephalopathy. A phenobarbital dose of 30 mg/kg is advised to reach therapeutic concentrations. Phenobarbital co-administration significantly increased midazolam clearance. Should phenobarbital be substituted by non-CYP3A inducers as first-line anticonvulsant, a 50% lower midazolam maintenance dose might be appropriate to avoid excessive exposure during the first days after birth.

© 2019 The Author(s)
Published by S. Karger AG, Basel

**Introduction**

Hypoxic-ischaemic encephalopathy (HIE) caused by perinatal asphyxia is a serious clinical condition with significant morbidity and mortality in (near-)term neonates. Globally, the incidence varies between 0.5 and 20 of every 1,000 live born neonates [1]. Therapeutic hypothermia (TH) is an established neuroprotective treatment which has markedly reduced the composite adverse outcome of death and neurodevelopmental disorders. In the Netherlands, 150–200 neonates are eligible for this treatment annually [2, 3].

Phenobarbital and midazolam are commonly prescribed drugs in this vulnerable population. Phenobarbital is a first-line anti-epileptic drug (AED). It acts through stimulation of the γ-aminobutyric acid (GABA) receptors in the central nervous system, which leads to a postsynaptic increase in chloride ions, thereby reducing neuronal excitability [4]. Phenobarbital has a half-life of approximately a week in neonates. Therefore, it can be administered as single or rapidly consecutive bolus administrations up to 40 mg/kg. Plasma concentrations between 20 and 40 mg/L are considered effective and safe [5]. Midazolam is a benzodiazepine which also interacts with the GABA receptor. It is used as a second-line AED when phenobarbital is ineffective [6]. Additionally, it is used for sedation in neonates who require mechanical ventilation [7]. Midazolam has a relatively short half-life of several hours in neonates and is usually administered via continuous infusion. For sedation, doses around 0.1 mg/kg/h are often sufficient, while as an AED, doses up to or even exceeding 0.3 mg/kg/h have been used. The therapeutic window for midazolam is not well defined but plasma concentrations of at least 0.1 mg/L are required for both indications. Higher plasma concentrations are associated with increased AED effectiveness [8]. Levels above 2.4 mg/L are considered toxic [9].

Midazolam undergoes hepatic metabolism by cytochrome P450 (CYP) 3A into 1-hydroxymidazolam (OHM). OHM is further metabolised into hydroxymidazolam glucuronide (HMG) which is excreted renally. Both metabolites are pharmacologically active, and accumulation has been associated with prolonged sedation [10, 11]. Phenobarbital is known as a potent inducer of several CYP enzymes in adults, including CYP3A [12].

Pharmacokinetics (PK) of drugs in neonates differs from older children and adults due to immaturity of the involved organs. CYP expression is impaired at birth but is subject to (rapid) maturation in the first few days of life [13, 14]. Midazolam clearance could potentially be increased if phenobarbital is also administered, but it is uncertain whether this drug-drug interaction is present in neonates. Induction of midazolam clearance might have important consequences for the use of this drug in this population since adequate control of neonatal seizures is important to reduce the risk of neurological disabilities [15–17].

Hypothermia could influence various physiological processes relevant for PK such as organ perfusion, protein binding, and (metabolic) enzymatic activity [18–20]. Previous studies from our group have assessed the effect of TH on PK of both phenobarbital and midazolam in this population using data from two tertiary neonatal intensive care units (NICU) as well as clinical effectiveness as AED [5, 8]. Clearance of neither drug was found to be affected by TH. Sufficient seizure control was achieved in 66% of all neonates with phenobarbital monotherapy.

**Phenobarbital and Midazolam Pharmacokinetics in Neonates**

DOI: 10.1159/000499330
When midazolam was started as a second-line AED, effectiveness was 23%.

The objective of the present study was to expand the current PK knowledge of phenobarbital and midazolam in neonates undergoing TH as treatment for HIE, to evaluate the previously developed models with an external dataset, to assess the effectiveness of each AED, and to develop PK-based dosing guidelines. In post hoc analyses, the influence of phenobarbital co-administration on midazolam clearance was investigated.

**Methods**

**Setting and Study Population**

The multi-centre prospective study PharmaCool was designed to investigate the PK of frequently used drugs during TH and rewarming in neonates suffering from HIE. Inclusion and exclusion criteria have been described previously [21]. Parental informed consent was obtained in all cases. The choice of therapy and drug dosing was not influenced by the study protocol. The PharmaCool study was approved by the Ethics Committees of all twelve participating NICUs in the Netherlands and Belgium.

**Dosing and Administration**

Phenobarbital was dosed as a single or repeated bolus short infusion of 10 of 20 mg/kg, up to a cumulative dose of 40 mg/kg. Midazolam was administered as continuous infusion, both for sedation and as AED, with a starting dose of 0.05 mg/kg/h for sedation and 0.1 mg/kg/h for seizure control and titrated to effect. Both regimens can be preceded by a loading dose of 0.05–0.1 mg/kg.

**Sampling and Bioanalysis**

Blood samples were drawn once daily on days 2–5 after birth both during hypothermia and rewarming/normothermia [21]. Plasma concentrations of phenobarbital, midazolam, OHM, and HMG were determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Details are available in the online Appendix (see www.karger.com/doi/10.1159/000499330 for all online suppl. material).

**Population Pharmacokinetic Analyses**

PK analyses were performed using non-linear mixed effects modelling NONMEM (version 7.3, Icon Development Solutions) [22]. Birth weight was used as a descriptor for body size and was related to pharmacokinetic parameters using allometric relationships. Based on previous publications from our group, a one-compartment model for phenobarbital and a one-compartment model for midazolam with consecutive one-compartment models for both metabolites were used as structural models [5, 8].

---

**Table 1. Patient characteristics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Phenobarbital (n = 113)</th>
<th>Midazolam (n = 118)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PB yes (n = 68)</td>
<td>PB no (n = 50)</td>
</tr>
<tr>
<td>Gestational age, weeks</td>
<td>39.8±1.7</td>
<td>40.2±1.4</td>
</tr>
<tr>
<td>Birth weight, g</td>
<td>3,382±582</td>
<td>3,450±540</td>
</tr>
<tr>
<td>Male</td>
<td>63 (55.8)</td>
<td>35 (51.5)</td>
</tr>
<tr>
<td>pHa</td>
<td>7.02 (6.85 to 7.15)</td>
<td>6.98 (6.80 to 7.10)</td>
</tr>
<tr>
<td>Lactatea, mmol/L</td>
<td>13.0 (9.0 to 18.2)</td>
<td>14.1 (11.4 to 16.6)</td>
</tr>
<tr>
<td>Base excessa, mmol/L</td>
<td>−18.0 (−12.0 to −22.0)</td>
<td>−18.0 (−22.0 to −12.0)</td>
</tr>
<tr>
<td>Thompson scoreb</td>
<td>9 (8–13)</td>
<td>10 (8 to 14)</td>
</tr>
<tr>
<td>Midazolam sedation only</td>
<td>–</td>
<td>33 (48.3)</td>
</tr>
<tr>
<td>Midazolam AED</td>
<td>–</td>
<td>35 (51.5)</td>
</tr>
<tr>
<td>Continuous normal voltage</td>
<td>16 (14.2)</td>
<td>8 (11.8)</td>
</tr>
<tr>
<td>Of whom &lt;5 μV</td>
<td>45 (39.8)</td>
<td>20 (29.4)</td>
</tr>
<tr>
<td>Burst suppression</td>
<td>26 (23.0)</td>
<td>21 (30.9)</td>
</tr>
<tr>
<td>Continuous low voltage</td>
<td>5 (4.4)</td>
<td>4 (5.9)</td>
</tr>
<tr>
<td>Flat trace</td>
<td>17 (15.0)</td>
<td>13 (19.1)</td>
</tr>
<tr>
<td>Unknown</td>
<td>4 (3.5)</td>
<td>2 (2.9)</td>
</tr>
<tr>
<td>Mortality</td>
<td>32 (28.3)</td>
<td>27 (39.7)</td>
</tr>
</tbody>
</table>

Data are presented as mean ± standard deviation, median (interquartile range), or n (%). PB, phenobarbital co-medication; AED, anti-epilpetic drug; aEEG, amplitude-integrated electroencephalogram. a Value measured in umbilical cord blood or, if unavailable, from arterial or venous blood within 1 h after birth. b Encephalopathy was characterized by a Thompson score of >7 1 h after birth or an abnormal aEEG (i.e., background pattern DNV <5 μV or worse or seizures) on admission to a level III NICU.
al age (GA), postnatal age (PNA), and body temperature (TEMP) were tested as covariates on clearance in both models. Phenobarbital co-medication was tested as covariate on clearance in the midazolam model. Parameter precision was assessed with sampling importance resampling [23].

**Anticonvulsant Effectiveness**

Treatment with phenobarbital was considered effective if no additional AED was started. In patients receiving midazolam for seizure control, effectiveness as second-line AED was defined as no requirement for a third-line AED.

**Dosing Guideline Development**

Several dosing regimens based on the current clinical practice were simulated using the parameter estimates of the final pharmacokinetic models. Phenobarbital single doses of 20, 30, and 40 mg/kg were evaluated. Midazolam was tested with a loading dose of 0.05 or 0.1 mg/kg followed by continuous infusions varying between 0.05 and 0.3 mg/kg/h.

**Results**

**Patient Characteristics**

Phenobarbital data were available for 113 patients. Cumulative doses varied between 4.9 and 62.6 mg/kg. Midazolam data were available from 118 patients (sedative \( n = 83 \), AED \( n = 35 \)). Of these, 68 (57.6%) were also treated with phenobarbital. Midazolam maintenance dose for sedation rarely exceeded 0.15 mg/kg/h. Highest midazolam maintenance dose as AED was 0.45 mg/kg/h. Patient characteristics are presented in Table 1.

Phenobarbital plasma concentrations were measured in 378 samples of which 219 (57.9%) were taken during TH. Plasma concentrations varied between 9.1 and 52.6 mg/L (Fig. 1). Plasma concentrations of midazolam, OHM and HMG were measured in 376 samples, of which 214 (56.9%) were taken during TH. Plasma concentrations for midazolam varied between 0.02 and 3.25 mg/L, for OHM between 0.02 and 1.05 mg/L, and for HMG between 0.02 and 8.34 mg/L (online Appendix).

**Population Pharmacokinetic Analyses**

Phenobarbital PK was best described by a one-compartment model. No influence of GA, PNA or TEMP could be detected on clearance. Midazolam PK was described by a one-compartment model with subsequent one-compartment models for OHM and HMG. GA and PNA did not affect clearance of any compound; TEMP significantly influenced only OHM clearance; clearance during TH was reduced by 25.7% \( (p < 0.05, 8.6\%/°C, 95\% \text{ CI} 5.6–11.5%/°C) \). Phenobarbital co-medication

---

**Fig. 1.** Observed phenobarbital plasma concentrations versus time after birth. Dotted lines indicate the proposed therapeutic window of 20–40 mg/L.
significantly influenced midazolam clearance. In absence of phenobarbital, midazolam clearance for a neonate of 3.5 kg was 0.35 L/h (95% CI 0.29–0.41 L/h). In patients with phenobarbital co-medication, midazolam clearance was 2.3-fold higher ($p<0.05$, 95% CI 1.9–2.9). This effect was consistent over the entire study period and independent of phenobarbital dose, TH, or indication for midazolam use. Pharmacokinetic parameter estimates of the final models are shown in Table 2. Further details of the population PK analyses are available in the online Appendix.

**Anticonvulsant Effectiveness**

Seizure control with phenobarbital monotherapy was achieved in 74 patients (65.5%). Thirty-five patients received midazolam as second-line AED. Of these, 22 (62.9%) also received lidocaine, levetiracetam, and/or clonazepam as additional AED. Midazolam was considered effective in the remaining 13 (37.1%) neonates. AED effectiveness is summarised in Table 3.

**Dosing Guideline Development**

Simulation datasets were created by replicating the patient characteristics of each neonate in the original dataset nine times, yielding simulation datasets of 1,017 patients for phenobarbital and 1,062 patients for midazolam. These datasets were used with the final PK parameter estimates to predict plasma concentrations after various dosing regimens.

Figure 3 shows predicted phenobarbital concentration-time curves after doses of 20, 30, and 40 mg/kg at PNA 4 h. With 20 mg/kg, 46.7% of patients are within the proposed therapeutic range (20–40 mg/kg) directly after bolus infusion, dropping to 18.7% at PNA 48 h. 30 mg/kg results in 90.2% within the therapeutic range directly after infusion and 85.4% at PNA 48 h. A dose of 40 mg/kg leads to 53.2% within the therapeutic range directly after infusion and 80.7% at PNA 48 h.

Figure 4 shows predicted concentration-time curves of midazolam with and without phenobarbital co-administration after a loading dose of 0.1 mg/kg followed by continuous infusion of 0.15 mg/kg/h.
Discussion

Data from this study confirm the previous findings that TH does not influence phenobarbital or midazolam clearance in neonates suffering from HIE. Clearance of OHM is reduced during TH compared to normothermia; clinicians should be aware that prolonged sedation could occur after cessation of midazolam during TH. Phenobarbital co-medication was found to significantly increase midazolam clearance. Although this effect has not been described previously, it has most likely been present in clinical practice for decades as both midazolam and phenobarbital are commonly used in neonates, often concomitantly for the treatment of seizures. Midazolam is usually titrated to the desired effect and/or tolerability of side effects independent of concomitant treatment with phenobarbital. Although adequate sedation and seizure control are crucial in neonates undergoing TH for HIE, concerns have been raised about both phenobarbital and midazolam use. Phenobarbital has been associated with neuronal toxicity in neonatal animal models and long-term cognitive and motor impairment in humans. Therefore, alternative first-line AEDs such as levetiracetam are currently being investigated [24]. As levetiracetam does not induce CYP3A, no influence on midazolam clearance is expected. In this situation, a reduction in midazolam maintenance dose by 50% is necessary to achieve similar plasma concentrations. Overexposure of midazolam should be avoided to minimize the risk of side effects such as hypotension and subsequent cerebral hypoperfusion when cerebral autoregulation is lost, and prolonged NICU admission [6, 8, 25, 26].

Table 2. Final model pharmacokinetic parameter estimates and SIR results

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Phenobarbital</th>
<th>Midazolam</th>
<th>OHM</th>
<th>HMG</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>estimate</td>
<td>SIR% 95% CI</td>
<td>estimate</td>
<td>SIR% 95% CI</td>
</tr>
<tr>
<td>Cl, L/h</td>
<td>10.3</td>
<td>8.38–12.1</td>
<td>0.353</td>
<td>0.286–0.441</td>
</tr>
<tr>
<td>V, L</td>
<td>3.60</td>
<td>3.43–3.79</td>
<td>5.42</td>
<td>4.49–6.81</td>
</tr>
<tr>
<td>TEMP on Cl, %/°C</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>PB on Cl, fold</td>
<td>NA</td>
<td>NA</td>
<td>2.33</td>
<td>1.88–2.92</td>
</tr>
</tbody>
</table>

Interindividual variability

<table>
<thead>
<tr>
<th></th>
<th>Phenobarbital</th>
<th>Midazolam</th>
<th>OHM</th>
<th>HMG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cl, variance (sd)</td>
<td>0.287 (34%)</td>
<td>0.148–0.498</td>
<td>0.628 (79.2%)</td>
<td>0.479–0.847</td>
</tr>
<tr>
<td>V, variance (sd)</td>
<td>0.0442 (36%)</td>
<td>0.0305–0.0659</td>
<td>0.934 (96.6%)</td>
<td>0.583–1.27</td>
</tr>
</tbody>
</table>

Residual variability

<table>
<thead>
<tr>
<th></th>
<th>Phenobarbital</th>
<th>Midazolam</th>
<th>OHM</th>
<th>HMG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cl, clearance (rse)</td>
<td>2.52 (33%)</td>
<td>2.32–2.79</td>
<td>0.01 (fixed)</td>
<td>NA (fixed)</td>
</tr>
<tr>
<td>Proportional, variance (sd)</td>
<td>NA</td>
<td>NA</td>
<td>0.126 (35.5%)</td>
<td>0.107–0.164</td>
</tr>
</tbody>
</table>

Covariance interindividual variability on Cl

<table>
<thead>
<tr>
<th></th>
<th>Phenobarbital</th>
<th>Midazolam</th>
<th>OHM</th>
<th>HMG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cl, variance (rsd)</td>
<td>0.087 (30%)</td>
<td>0.063–0.126</td>
<td>0.214 (35.0%)</td>
<td>0.133–0.310</td>
</tr>
</tbody>
</table>

Table 3. Effectiveness of phenobarbital and midazolam as anti-epileptic drugs

<table>
<thead>
<tr>
<th></th>
<th>Effective</th>
<th>Ineffective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenobarbital (n = 113)</td>
<td>74 (65.5)</td>
<td>39 a (34.5)</td>
</tr>
<tr>
<td>Midazolam (n = 35)</td>
<td>13 (37.1)</td>
<td>22 (62.9)</td>
</tr>
</tbody>
</table>

Data are presented as n (%). a Four patients unresponsive to phenobarbital received lidocaine instead of midazolam as second-line anti-epileptic drug.

CYP3A is the most abundant subfamily of cytochrome P450 isozymes in the human liver and consists of at least three isoforms: CYP3A4, CYP3A5, and CYP3A7 [27]. CYP3A4 activity is relatively low at birth but increases over the first few weeks of life and reaches adult capacity between 6–12 months after birth. In adult livers, it accounts for 30–40% of all CYP content [27, 28]. CYP3A5 is present at a much lower level compared to CYP3A4 and shows large interindividual variability. No maturational pattern of CYP3A5 has been identified [28]. CYP3A7 is
the major CYP isoform detected in the embryonic, foetal, and newborn liver but decreases thereafter. Compounds metabolised by CYP3A4 in adults are most likely primarily metabolised by CYP3A7 in neonates and infants up to 3 months of age [28, 29].

Induction of CYP enzymes is caused by an increase in gene transcription followed by upregulation of enzyme production. Unlike CYP inhibition, which is an almost immediate response, it is believed that CYP induction is a slower regulatory process which accumulates over time [30]. In adults, clinically relevant CYP3A induction has been described within 24 h after administration [31]. In asphyxiated neonates, both phenobarbital and midazolam are often administered within the first few hours after birth. In this study, blood sampling commenced on the second day after birth. As a time-dependent effect of...
Phenobarbital and Midazolam Pharmacokinetics in Neonates

Phenobarbital on midazolam clearance was not identified, we hypothesise that the increasing effect of phenobarbital on CYP3A production in this population is clinically relevant as early as 24 h after birth.

In the past, phenobarbital has been used to treat hyperbilirubinaemia in predominantly preterm infants by inducing glucuronidation of unconjugated bilirubin [32]. Although OHM is glucuronated into HMG, no effect of phenobarbital co-medication on OHM clearance was identified. It is possible that glucuronidation is more developed in term neonates and that induction of glucuronidation is only relevant in preterm neonates as phenobarbital was unsuccessful in preventing hyperbilirubinaemia in term neonates [33]. Also, to our knowledge no drug-drug interactions between phenobarbital and drugs undergoing glucuronidation have been described in humans.

Table 1 clearly shows a difference in baseline characteristics between midazolam patients with and without phenobarbital co-administration. Neonates with phenobarbital co-medication had a more suppressed aEEG on admission and higher mortality, suggesting a more severe disease state.

However, increased midazolam clearance in this group by induction of CYP3A indicates that hepatic metabolic capacity is unaffected even in the most severe HIE cases.

Based on simulations performed in this study, a phenobarbital loading dose of 30 mg/kg is recommended to achieve plasma concentrations within the therapeutic window. An additional dose of 10 mg/kg can be given if seizures persist. This advice is in line with a recent study investigating phenobarbital PK in non-asphyxiated term and preterm neonates [34]. Phenobarbital effectiveness is comparable to previous reports [4, 5].

No changes to the midazolam dosing regimens are required in the current clinical practice. However, should phenobarbital be replaced as first-line AED, midazolam for additional seizure control should be titrated more carefully. Although responsiveness to midazolam in this study was higher than previously reported, its effectiveness as second-line AED remains limited [4, 8].

The data for this study were collected in neonates with a GA of ≥36 weeks treated with TH for HIE. However, we believe that the interaction between phenobarbital and midazolam can be extrapolated to (near-)term neonates in general. As liver function might be hampered by TH and/or HIE, the magnitude of the effect in non-asphyxiated normothermic neonates could be even greater. Extrapolation to preterm neonates should be done with caution due to possible maturational differences in CYP enzymes [13].

Conclusion

PK of phenobarbital and midazolam is unaffected by TH in (near-)term neonates treated with TH for HIE, and clinical effectiveness is comparable to previous reports. Phenobarbital significantly increased midazolam clearance. Should phenobarbital be substituted by non-CYP-inducing drugs as first-line anticonvulsant, a lower midazolam dose is necessary to avoid excessive exposure across the entire neonatal population.

Acknowledgements

The following PharmaCool study group members are non-author contributors: Mieke J. Brouwer, PhD; S.M. Mulder-de Tol lenaar, MD, PhD; L.J.M. Groot Jebbink-Akkerman, MD, PhD; Dijen Liem, MD, PhD; Katerina Steiner, MD, PhD; Jeroen Dudink, MD, PhD; Rogier C.J. de Jonge MD, PhD;annelies A. Bos, MD, PhD; Michel Sonnaert, MD, PhD; Fleur Anne Camffer man, MD, PhD. Affiliations correspond with author affiliations.

The authors would like to thank Mark de Groot for contributions with regard to data management.

Fig. 4. Simulated midazolam plasma concentrations after a loading dose of 0.1 mg/kg followed by continuous infusion of 0.15 mg/kg/h. Upper solid line indicates the mean midazolam plasma concentration without phenobarbital co-medication. Bottom solid line indicates the mean midazolam plasma concentration with phenobarbital co-medication; grey areas represent the interquartile ranges.
El-Dib M, Soul JS. The use of phenobarbital


El-Dib M, Soul JS. The use of phenobarbital

References


4 El-Dib M, Soul JS. The use of phenobarbital


